Proto Labs Reports Record Q3 Revenue of $135.4 Million

Reuters
Oct 31
Proto Labs Reports Record Q3 Revenue of $135.4 Million

Proto Labs Inc. reported record revenue of $135.4 million for the third quarter of 2025, a 7.8% increase compared to $125.6 million in the same period of 2024. Revenue fulfilled through digital factories reached $105.3 million, up 4.9% year-over-year, while revenue fulfilled through the Protolabs Network was $30.1 million, a 19.1% increase. Net income was $7.2 million, or $0.30 per diluted share, compared to $7.2 million, or $0.29 per diluted share, in the third quarter of 2024. Non-GAAP net income was $11.4 million, or $0.47 per diluted share, unchanged from the prior year. The company served 21,252 customer contacts during the quarter, with revenue per customer contact rising 14.1% year-over-year to $6,370. EBITDA was $17.4 million, while adjusted EBITDA was $21.1 million, representing 15.6% of revenue. Cash from operations totaled $29.1 million, and the cash and investments balance was $138.4 million as of September 30, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Proto Labs Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251031425232) on October 31, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10